← Ultragenyx Pharmaceutical Inc.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | ($245.9m) | ($302.1m) | ($197.6m) | ($402.7m) | ($186.6m) | ($454.0m) | ($707.4m) | ($606.6m) | ($569.2m) | ($575.0m) | — | |
| Depreciation, Depletion and Amortization | $3.4m | $5.8m | $19.5m | $8.5m | $12.3m | $13.2m | $18.2m | $26.0m | $35.5m | $35.0m | $33.0m | |
| Deferred Income Tax Expense (Benefit) | — | ($16.2m) | — | $2.1m | — | — | ($1.6m) | $1.8m | $1.4m | — | — | |
| Share-based Payment Arrangement, Noncash Expense | $48.3m | $68.0m | — | — | — | — | — | — | — | — | $139.0m | |
| Share-based Payment Arrangement, Expense | $48.3m | $68.0m | $80.1m | $82.0m | $85.7m | $105.0m | $130.4m | $135.2m | $158.1m | $153.0m | $139.0m | |
| Goodwill and Intangible Asset Impairment | — | — | $0 | $0 | $0 | $0 | — | — | — | — | — | |
| Nonoperating Income (Expense) | $2.2m | — | — | — | — | — | — | — | — | — | — | |
| Other Nonoperating Income (Expense) | ($1.6m) | $6.5m | ($5.6m) | ($787k) | $607k | ($1.7m) | ($1.6m) | ($337k) | ($4.0m) | $1.0m | — | |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts Receivable | — | — | $7.6m | $20.1m | ($9.8m) | $5.4m | $12.1m | $22.8m | $33.6m | $31.0m | ($71.0m) | |
| Increase (Decrease) in Inventories | — | — | $5.3m | $4.5m | $1.3m | $3.1m | $9.7m | $6.9m | $11.2m | $6.0m | ($12.0m) | |
| Increase (Decrease) in Accounts Payable | $2.5m | $3.5m | $3.4m | — | — | — | — | — | — | — | $49.0m | |
| Net Cash Provided by (Used in) Operating Activities | ($161.0m) |
($253.8m)
-57.69%
|
($290.6m)
-14.47%
|
($345.4m)
-18.87%
|
($132.2m)
+61.72%
|
($338.7m)
-156.16%
|
($380.5m)
-12.33%
|
($474.8m)
-24.80%
|
($414.2m)
+12.77%
|
($466.0m)
-12.51%
|
($485.0m)
-4.08%
|
|
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Property, Plant, and Equipment | $10.2m | $2.8m | $4.1m | $24.8m | $43.9m | $73.1m | $116.1m | $44.3m | $7.5m | $6.0m | ($9.0m) | |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale | $403.2m | $273.6m | $302.6m | $676.2m | $589.8m | $718.1m | $450.7m | $695.5m | $410.0m | $444.0m | — | |
| Payments to Acquire Businesses, Net of Cash Acquired | — | $142.8m | — | — | — | — | $75.0m | $0 | $0 | — | $0 | |
| Payments for (Proceeds from) Other Investing Activities | — | — | — | — | $5.6m | $942k | $844k | $5.0m | $2.4m | $1.0m | — | |
| Net Cash Provided by (Used in) Investing Activities | $89.9m | $56.4m | ($33.3m) | ($13.0m) | ($179.1m) | ($195.4m) | ($291.7m) | $168.0m | ($17.8m) | $236.0m | $40.0m | |
| Cash flows from financing activities: | ||||||||||||
| Proceeds from Issuance of Common Stock | — | — | $271.0m | $330.4m | $435.6m | $0 | $0 | $326.5m | $381.0m | $0 | $5.0m | |
| Proceeds from (Payments for) Other Financing Activities | — | — | — | — | ($236k) | ($492k) | ($555k) | ($28k) | $0 | $0 | — | |
| Net Cash Provided by (Used in) Financing Activities | $138.7m |
$136.3m
-1.74%
|
$336.9m
+147.20%
|
$679.3m
+101.66%
|
$600.3m
-11.63%
|
$118.6m
-80.25%
|
$501.2m
+322.77%
|
$388.1m
-22.56%
|
$399.2m
+2.86%
|
$478.0m
+19.73%
|
$397.0m
-16.95%
|
|
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $68.8m | ($61.6m) | $12.5m | $320.7m | $290.1m | ($416.7m) | ($172.0m) | $81.8m | ($35.2m) | $252.0m | $185.5m | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Proceeds from Stock Options Exercised | — | $7.8m | $25.8m | $7.7m | $88.1m | $36.6m | $6.2m | $2.7m | $5.7m | $0 | — | |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, Net | $35k | $16.2m | $514k | $3.3m | $1.2m | $1.0m | $5.7m | $1.8m | $1.6m | $4.0m | — | |
| Additional Financial Items | ||||||||||||
| Equity Securities, FV-NI, Gain (Loss) | — | — | — | $13.4m | $170.4m | ($42.1m) | ($19.3m) | $397k | ($1.1m) | — | — | |
| Foreign Currency Transaction Gain (Loss), before Tax | ($1.3m) | $7.0m | ($5.3m) | ($688k) | $221k | — | — | — | — | — | — | |
| Gain (Loss) on Disposition of Intangible Assets | — | — | $170.3m | — | — | — | — | — | — | — | — | |
| General and Administrative Expense | $64.9m | — | — | — | — | — | — | — | — | — | — | |
| Goodwill | — | $44.4m | $44.4m | $44.4m | $44.4m | $44.4m | $44.4m | $44.4m | $44.4m | $44.0m | — | |
| Investment Income, Interest | $3.8m | $4.1m | $9.5m | $13.2m | $7.0m | $1.9m | $11.1m | $26.7m | $36.5m | $25.0m | — | |
| Operating Expenses | $248.1m | $331.6m | $422.9m | $527.9m | $601.1m | — | — | — | — | — | — | |
| Proceeds from Noncontrolling Interests | — | — | — | — | — | — | — | — | $7.0m | $0 | — |